Novabay Pharmaceuticals Inc (AMEX:NBY) shares, rose in value on Friday, April 26, with the stock price up by 11.23% to the previous day’s close as strong demand from buyers drove the stock to $0.09.
Actively observing the price movement in the recent trading, the stock is buoying the session at $0.08. Referring to stock’s 52-week performance, its high was $1.42, and the low was $0.06. On the whole, NBY has fluctuated by -22.99% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 14.8M, with a low estimate of 3M and a high estimate of 3.56M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 3.28M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NBY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of NBY currently trading nearly -4.22% and -29.94% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.61, while the 7-day volatility ratio is showing 15.16% which for the 30-day chart, stands at 12.03%. Furthermore, Novabay Pharmaceuticals Inc (NBY)’s beta value is 2.05, and its average true range (ATR) is 0.01.
A comparison of Novabay Pharmaceuticals Inc (NBY) with its peers suggests the former has fared considerably weaker in the market. NBY showed an intraday change of 11.23% in today’s session so far, and over the past year, it shrunk by -93.73%%.
Data on historical trading for Novabay Pharmaceuticals Inc (AMEX:NBY) indicates that the trading volumes over the past 3 months, they’ve averaged 3.59 million. According to company’s latest data on outstanding shares, there are 36.06 million shares outstanding.
Nearly 0.04% of Novabay Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 3.30% of the company’s shares. The stock has fallen by -58.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NBY stock heading into the next quarter.
